CLINICAL STUDY
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
Dermot Cox, BSc, PhD*,
Richard Smith, BSc, PhD*,
Martin Quinn, MD*,
Pierre Theroux, MD ,
Peter Crean, MD and
Desmond J. Fitzgerald, MD*
* Centre for Cardiovascular Science, Royal College of Surgeons in Ireland, Dublin, Ireland
Montreal Heart Institute, Montreal, Quebec, Canada
Department of Cardiology, St. James Hospital, Dublin, Ireland
Manuscript received January 13, 2000;
revised manuscript received April 26, 2000,
accepted June 26, 2000.
Reprint requests and correspondence: Dr. Dermot Cox, Department of Clinical Pharmacology, Royal College of Surgeons, 123 St. Stephen’s Green, Dublin 2, Ireland.
dcox{at}rcsi.ie
OBJECTIVES
The study was done to determine the role of partial agonist activity in the lack of effectiveness of the oral GPIIb/IIIa antagonist orbofiban.
BACKGROUND
Orbofiban, an oral GPIIb/IIIa antagonist, was found to increase the mortality of patients with acute coronary syndromes (ACS) in the OPUS-TIMI-16 trial, despite the fact that it is a very potent anti-platelet agent and that IV agents have proven very effective.
METHODS
Patients (n = 520) with ACS were randomized to orbofiban 30 mg, 40 mg or 50 mg twice daily or 50 mg once daily or placebo. Platelet activity was assessed in 175 patients by examining GPIIb/IIIa receptor conformation, expression of CD63 antigen, and platelet aggregation.
RESULTS
Plasma concentrations of orbofiban at the highest dose (74 ± 6 ng/ml peak, 61 ± 5 ng/ml trough) exceeded the IC50 for platelet aggregation to adenosine diphosphate (ADP) (29 ± 6 ng/ml) and thrombin-activating peptide (61 ± 18 ng/ml). Orbofiban induced a conformational change in GPIIb/IIIa detected as the displacement of the monoclonal antibody mAb2; such conformational changes have been linked to partial agonist activity. Consistent with this, platelet expression of CD63 ex vivo was significantly increased at five time points during the study. In vitro, orbofiban increased platelet aggregation to a submaximal concentration of epinephrine (67 ± 19% vs. 27 ± 9%, n = 5) and increased thromboxane formation when the platelet GPIIb/IIIa were clustered using monoclonal antibodies to the receptor.
CONCLUSIONS
Orbofiban is both an antagonist and a partial agonist of platelet GPIIb/IIIa. At low concentrations of the drug, this partial agonist activity may enhance platelet aggregation. Along with suboptimal plasma drug levels, these findings may help explain the lack of efficacy seen with orbofiban in patients with ACS.
|
Abbreviations and Acronyms
| | ADP | = adenosine diphosphate | | ANOVA | = analysis of variance | | FSC | = forward scatter | | GPIIb/IIIa | = platelet fibrinogen receptor | | IV | = intravenous | | MI | = myocardial infarction | | PBS | = phosphate buffered saline | | PRP | = platelet-rich plasma | | SSC | = side scatter | | TRAP | = thrombin receptor activating peptide |
|
This article has been cited by other articles:
|
|
|
|
 
R. Blue, M. Murcia, C. Karan, M. Jirouskova, and B. S. Coller
Application of high-throughput screening to identify a novel {alpha}IIb-specific small- molecule inhibitor of {alpha}IIb{beta}3-mediated platelet interaction with fibrinogen
Blood,
February 1, 2008;
111(3):
1248 - 1256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
Vascular Medicine,
May 1, 2007;
12(2):
113 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Bassler, C. Loeffler, P. Mangin, Y. Yuan, M. Schwarz, C. E. Hagemeyer, S. U. Eisenhardt, I. Ahrens, C. Bode, S. P. Jackson, et al.
A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic {alpha}IIb{beta}3 (GPIIb/IIIa) Antagonists
Arterioscler Thromb Vasc Biol,
March 1, 2007;
27(3):
E9 - E15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Freedman
Molecular Regulation of Platelet-Dependent Thrombosis
Circulation,
October 25, 2005;
112(17):
2725 - 2734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Aster
Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa Inhibitors
Chest,
February 1, 2005;
127(2_suppl):
53S - 59S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
234S - 264S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xiao and P. Theroux
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
1982 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schwarz, Y. Katagiri, M. Kotani, N. Bassler, C. Loeffler, C. Bode, and K. Peter
Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa ({alpha}IIb{beta}3, CD41/CD61)
J. Pharmacol. Exp. Ther.,
March 1, 2004;
308(3):
1002 - 1011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dalby, G. Montalescot, C. B. d. Sollier, E. Vicaut, T. Soulat, J.-P. Collet, R. Choussat, V. Gallois, G. Drobinski, L. Drouet, et al.
Eptifibatide provides additional platelet inhibition in Non-ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in Non-Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study
J. Am. Coll. Cardiol.,
January 21, 2004;
43(2):
162 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al.
Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology
Eur. Heart J.,
January 2, 2004;
25(2):
166 - 181.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J Knight
Antiplatelet treatment in stable coronary artery disease
Heart,
October 1, 2003;
89(10):
1273 - 1278.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Quinn, T. V. Byzova, J. Qin, E. J. Topol, and E. F. Plow
Integrin {alpha}IIb{beta}3 and Its Antagonism
Arterioscler Thromb Vasc Biol,
June 1, 2003;
23(6):
945 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. de Lemos, D. A. Morrow, M. S. Sabatine, S. A. Murphy, C. M. Gibson, E. M. Antman, C. H. McCabe, C. P. Cannon, and E. Braunwald
Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes
Circulation,
February 11, 2003;
107(5):
690 - 695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mirabet, D. Garcia-Dorado, J. Inserte, J. A. Barrabes, R.-M. Lidon, B. Soriano, M. Azevedo, F. Padilla, L. Agullo, M. Ruiz-Meana, et al.
Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts
Am J Physiol Heart Circ Physiol,
September 1, 2002;
283(3):
H1134 - H1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Quinn, E. F. Plow, and E. J. Topol
Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?
Circulation,
July 16, 2002;
106(3):
379 - 385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Peter, M. Schwarz, C. Bode, A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, and A. D. Michelson
Activating Effects of GPIIb/IIIa Blockers: An Intrinsic Consequence of Ligand- Mimetic Properties * Response
Circulation,
May 28, 2002;
105
(21):
e180 - e181.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, D. J. Moliterno, M. Bertrand, F.-J. Neumann, H. C. Herrmann, E. R. Powers, C. L. Grines, J. W. Moses, D. J. Cohen, E. A. Cohen, et al.
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial*
Circulation,
May 21, 2002;
105(20):
2347 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.W.G. Leebeek, E. Boersma, C.P. Cannon, F.J.J. van de Werf, and M.L. Simoons
Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable
Eur. Heart J.,
March 2, 2002;
23(6):
444 - 457.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono
Antiplatelet strategies
Eur. Heart J. Suppl.,
February 1, 2002;
4(suppl_A):
A42 - A47.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. F. O'Connor, D. C. Shields, A. Fitzgerald, C. P. Cannon, E. Braunwald, and D. J. Fitzgerald
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes
Blood,
December 1, 2001;
98(12):
3256 - 3260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vermylen, M. Hoylaerts, J. Arnout, D. P. Chew, D. L. Bhatt, E. J. Topol, and S. Sapp
Increased Mortality With Long-Term Platelet Glycoprotein IIb/IIIa Antagonists: An Explanation? Response
Circulation,
November 13, 2001;
104
(20):
e109 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Fitzgerald
Vascular biology of thrombosis: The role of platelet-vessel wall adhesion
Neurology,
September 1, 2001;
57(90002):
S1 - 4.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Curtin and D.J. Fitzgerald
A cold start for oral glycoprotein IIb/IIIa antagonists
Eur. Heart J.,
December 2, 2000;
21(24):
1992 - 1994.
[PDF]
|
|
|
|
